Vista Pharmaceuticals Ltd - 524711 - Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Board outcome
📍 Board approved audited standalone results for quarter and year ended 31 March 2026.
📍 Board approved unmodified auditor opinion for FY26.
📍 LMN & Co. appointed internal auditors for FY27.
FY26 financials
📊 Revenue from operations fell to ₹539.95 lakh from ₹1,007.46 lakh.
📊 Total income declined to ₹571.52 lakh from ₹1,051.52 lakh.
📊 Loss before tax widened to ₹1,615.11 lakh from ₹528.99 lakh.
📊 Net loss rose to ₹1,206.12 lakh from ₹464.81 lakh.
📊 Other expenses increased to ₹1,259.48 lakh from ₹375.30 lakh.
📊 Finance costs rose to ₹110.10 lakh from ₹79.79 lakh.
📊 Basic and diluted EPS were both negative ₹1.96.
Q4 FY26
📊 Revenue from operations was ₹241.82 lakh versus ₹323.00 lakh a year earlier.
📊 Total income was ₹245.10 lakh versus ₹337.06 lakh a year earlier.
📊 Loss before tax was ₹776.88 lakh versus ₹106.21 lakh a year earlier.
📊 Net loss was ₹586.29 lakh versus ₹149.57 lakh a year earlier.
Cash flow and balance sheet
📊 Operating cash outflow was ₹440.09 lakh in FY26.
🧱 Capex on fixed assets, including CWIP, was ₹76.21 lakh.
📊 Cash and bank balances ended at ₹10.70 lakh.
📊 Trade receivables fell to ₹220.05 lakh from ₹1,015.16 lakh.
📊 Inventories rose to ₹1,100.93 lakh from ₹822.01 lakh.
📊 Total equity stood at ₹3,644.08 lakh, down from ₹4,542.25 lakh.
Working capital and liabilities
⚠️ Company reported negative working capital of ₹1,318.6 lakh.
⚠️ Statutory dues outstanding included TDS, PF, ESI, professional tax and income tax.
⚠️ Company disclosed defaults in loan repayments.
⚠️ Continuing employee benefit contribution defaults were disclosed.
Going concern and impairment
⚠️ Financial statements were prepared on a going concern basis despite material uncertainty.
⚠️ Company cited five consecutive years of losses and Bank of Baroda term-loan defaults.
⚠️ Trade receivables impairment allowance of ₹821.74 lakh was recognized.
⚠️ Receivables were written off after management concluded recovery was not reasonably certain.
Capital structure
📊 Company issued 1,02,49,998 convertible share warrants during the year.
📊 25% upfront consideration of ₹307.51 lakh was received against warrants.
📊 Balance warrant consideration of about ₹922.50 lakh remains receivable on exercise.
Business and operations
Pharmaceutical manufacturing is the company’s only operating segment.
The company holds valid drug manufacturing licences.
CWIP of ₹1,061.21 lakh relates to the pharmaceutical R&D pipeline.
Auditor
📍 Statutory auditors issued an unmodified opinion on FY26 audited results.
OthersFormat of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Vista Pharmaceuticals Ltd - 524711 - Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025.
2. Limited Review Report Quarter And Nine Months 31.12.2025.
3. Any Other Business With The Permission Of The Chair.
🗓️ Meeting Details
Board meeting scheduled for February 13, 2026, at the company's registered office.
📊 Financial Performance
Consideration of unaudited financial results for the quarter and nine months ended December 31, 2025.
Review of Limited Review Report for the quarter and nine months ended December 31, 2025.